Welcome to our dedicated page for Kazia Therapeuti SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kazia Therapeutics Limited (NASDAQ: KZIA) files as a foreign private issuer with the U.S. Securities and Exchange Commission, primarily using Form 20-F for annual reporting and Form 6-K for current reports. This SEC filings page for KZIA brings together those regulatory documents and pairs them with AI-generated summaries to help readers interpret the company’s disclosures.
For a clinical-stage oncology company like Kazia, Form 6-K reports often incorporate press releases and transaction details by reference. Recent 6-K filings describe private placements of equity securities, the terms of pre-funded warrants and American Depositary Shares, at-the-market offering agreements, and collaboration and in-licensing arrangements such as the PD-L1 protein degrader program with QIMR Berghofer. Other 6-Ks discuss Nasdaq listing notices, the company’s responses, and subsequent steps taken to regain or demonstrate compliance with listing standards.
These filings also reference how capital raised is intended to support the continued clinical development of Kazia’s lead programs, including paxalisib, a brain-penetrant PI3K / Akt / mTOR pathway inhibitor, and EVT801, a VEGFR3 inhibitor, as well as the PD-L1 degrader program. Supplemental risk factor disclosures in certain filings provide additional detail on regulatory approval processes, combination therapy development, and ongoing regulatory obligations after any potential approvals.
On this page, AI-powered tools can help explain the structure and implications of Kazia’s 6-K filings, highlight key terms in financing agreements, and summarize how new collaborations or regulatory updates relate to the company’s oncology pipeline. Users can also review references to incorporated press releases, understand how offerings may affect capital structure, and see how Kazia describes its strategy for maintaining Nasdaq listing and advancing its investigational cancer therapies.
Kazia Therapeutics Limited filed a prospectus supplement registering 10,700,211 American Depositary Shares (representing 5,350,105,500 ordinary shares) to update the Prospectus dated December 23, 2025.
The supplement incorporates a Form 6-K that attaches the Company’s half‑year report for the six months ended 31 December 2025, reporting a loss after tax of $12,552,490 and cash and cash equivalents of $69,459,980. The supplement notes the ADSs trade on Nasdaq under the symbol KZIA and references private placement activity, including a December PIPE with reported net proceeds of US$46,509,833.
Kazia Therapeutics Limited is registering 266,666 American Depositary Shares representing 133,333,000 ordinary shares.
This prospectus supplement (to the December 22, 2025 prospectus) incorporates a Form 6-K furnished on March 19, 2026 and discloses the company’s half-year results for the six months ended 31 December 2025. The half‑year report shows a loss after tax of $12,552,490 and cash and cash equivalents of $69,459,980 as of 31 December 2025. The report also describes two private placements during the period, including a December 2025 placement with net proceeds of approximately $46.5M and an earlier placement of approximately $2.0M. The ADSs trade on Nasdaq under the symbol KZIA; the last reported sale price on March 18, 2026 was $7.51 per ADS.
Kazia Therapeutics Limited filed a prospectus supplement registering 232,956 American Depositary Shares, representing 116,478,000 ordinary shares, as set out in a prospectus supplement dated March 19, 2026.
The half‑year report for the six months ended 31 December 2025 shows a loss after tax of $12,552,490 and cash and cash equivalents of $69,459,980. Directors state the financial statements are prepared on a going concern basis. The company completed a private placement in December 2025 with expected net proceeds of $46.5 million to support clinical programs including paxalisib.
Registration covers 95,110 American Depositary Shares representing 47,555,000 ordinary shares, as set forth in a prospectus supplement to the Form F-1.
This supplement incorporates a Form 6-K dated March 19, 2026 attaching the company’s half‑year report for the six months ended 31 December 2025. The half‑year report shows a loss after tax of $12,552,490 and cash and cash equivalents of $69,459,980 as at 31 December 2025. The report discloses recent capital raises, including a private placement with net proceeds of approximately $46,509,833 and material issuances of ordinary shares and pre‑funded warrants closed in December 2025.
Kazia Therapeutics Limited reported an unaudited half-year loss of $12,552,490 for the six months ended 31 December 2025, wider than the prior period. Operating cash outflow was $9,540,623, reflecting ongoing pharmaceutical R&D spending.
Despite the loss, Kazia dramatically strengthened its balance sheet. Cash and cash equivalents rose to $69,459,980 at 31 December 2025, up from $4,344,691 at 30 June 2025, driven by equity financing and pre-funded warrant issuances totaling $75,321,410 of net cash inflow.
Net assets improved to $46,467,039, compared with a net liability position of $(8,301,449) at the previous year-end, helped by a large December private placement and ATM issuances that increased ordinary shares on issue to 5.67 billion. The company advanced its lead asset paxalisib in breast cancer and glioblastoma, and entered a new PD-L1 degrader collaboration, while auditors issued a clean review conclusion on the half-year accounts.
Kazia Therapeutics director Steven R. S. Coffey filed an initial ownership report showing his equity interests in the company. He holds options over 1,000 American Depositary Shares (ADSs) at an exercise price of $0.3348 expiring on April 30, 2027, granted on April 30, 2024 with quarterly vesting over three years, and options over 75,000 ADSs at $8.00 expiring on July 3, 2027, which vested fully on July 3, 2025. He also directly owns 16,000 ordinary shares. Additional ADS holdings of 845 and 1,122 are held by Coffey Family Investments Pty Limited and Fortune 501 Pty Limited, respectively, and Coffey disclaims beneficial ownership of those securities except for any pecuniary interest. Each ADS may be exchanged at any time for 500 ordinary shares, and the ADSs themselves have no expiration date.
Kazia Therapeutics filed an initial ownership report for Chief Executive Officer John E. Friend II, showing he holds several option awards rather than recent market trades. These options give him the right to buy both American Depositary Shares (ADSs) and ordinary shares at preset prices before their expiration dates.
He holds ADS options over 30,000 ADSs at an exercise price of $0.3770 per ADS expiring on July 22, 2027, and over 500,000 ADSs at $6.5800 per ADS expiring on July 3, 2027. He also holds ordinary share options over 3,000,000 shares at $0.1323 per share expiring on May 3, 2027, and 1,000,000 ordinary shares at $0.1061 per share expiring on March 3, 2027.
Footnotes explain that these options vest in quarterly or annual installments starting between 2023 and 2025, subject to his continued service, and that exercise prices are reported in U.S. dollars based on a stated AUD/USD exchange rate. No purchases or sales occurred; this filing mainly outlines his existing equity-based compensation.
Kazia Therapeutics Program Director Jeremy Simpson filed an initial Form 3 reporting existing option holdings in the company. He holds options over 280,000 ordinary shares with a $0.1061 exercise price expiring on March 3, 2027, and options over 100,000 ordinary shares with a $0.6651 exercise price expiring on February 1, 2027. Footnotes explain these options were granted in 2022 and 2023 and vest in scheduled installments, reflecting compensation awards rather than new market transactions.
Kazia Therapeutics VP, Finance and Controller Jeffrey Bonacorda has reported initial holdings of stock options over American Depositary Shares. The filing shows options over 5,000 ADSs at an exercise price of 0.23 expiring on 2028-06-24, and options over 100,000 ADSs at 6.58 expiring on 2027-07-03. These awards vest in annual installments starting on June 24, 2024 and July 3, 2025, contingent on continued service.